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LETTERS TO THE EDITOR 
Morbidity and Mortality with PUVA: Colonic Cancer 
(The Reply to this letter appeared in /ID 92646, 1989.) 
To the Editor: 
Cancer, according to some authors, has a lower incidence in patients 
with psoriasis [ 11. In the recent article from Stern et al [2], there was 
a significant increase in the incidence of colonic cancer after ten 
years of prospective study of a cohort of 1380 patients with psoriasis 
who had received photochemotherapy (PUVA). There may be an 
explanation for this unexpected finding from what is already known 
about the association between ulcerative colitis and psoriasis, and 
the risk of colonic cancer in ulcerative colitis. 
In a prospective study of skin disease in 142 patients with inflam- 
matory bowel disease, Verbov [3] showed a 7.5% prevalence of 
psoriasis in ulcerative colitis, which is substantially higher than the 
estimated prevalence of psoriasis in North-West Europeans, rated at 
1.5% -2.5% [4,5]. Yates et al [6] subsequently confirmed a signifi- 
cantly greater prevalence of psoriasis (5.7%) in ulcerative colitis 
than in the control group (1.50/) o , and an increased prevalence in 
first-degree relatives of patients with inflammatory bowel disease. It 
has therefore been suggested that there is a relationship between 
psoriasis and inflammatory bowel disease which may be explained 
by shared genetic factors or histocompatibility antigen linkage. 
As the risk of colonic cancer in patients with ulcerative colitis is 
between five and ten times greater than in the general population 
[7], it is tempting to speculate that there is a higher incidence of 
colonic cancer in the PUVA follow-up study owing to a preponder- 
ance of patients with ulcerative colitis in the psoriasis group. 
Unless the authors are able to establish the number of patients 
with ulceraive colitis in their study and control groups, this infor- 
mation should be collated from further large studies of morbidity 
and mortality in psoriatic patients. 
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HNK-1 Antigen is Not Specific for Natural Killer Cells 
To the Editor: 
We were interested to read the article by Habets et al [l] and the 
subsequent correspondence published in the October 1988 issue [2, 
31 regarding natural killer (NK) cells around basal cell carcinomas 
(BCCs) and the suitability of the HNK-1 antigen as a marker for 
such cells. We agree with Manara that the HNK-1 antigen is not 
NK cell specific. The nomenclature committee at the recent 5th 
NK International Workshop, March 1988 [4] defined NK cells as 
commonly having CD16 (Leu 11) and NKH-1 (Leu 19) antigens; 
HNK-1 antigen was not a defining feature. 
Both Habets and Manara suggest further studies into the presence 
of CD16 and NKH-1 antigens to clarify the possible role of NK 
cells in defense against BCC. We have just completed such a study 
detailing reactivity of cells with Leu 7, Leu 11, and Leu 19 antibod- 
ies in a range of benign and malignant epidermal tumors (38 cases) 
and inflammatory dermatoses (20 cases). 
HNK-1 (Leu 7)-positive cells were found in all cases of tumors 
and dermatoses, whereas CD16 (Leu ll)- and NKH-1 (Leu 19)- 
positive cells showed a much more restricted tissue distribution 
with positive cells mainly associated with cases of squamous cell 
carcinoma and keratoacanthoma. Comparison of serial sections 
showed a clear disparity between positive cells using Leu 7 and Leu 
1 l/Leu 19. As the majority of cells in peripheral blood that demon- 
strate NK activity share the CD3 - ve, CD16 i- ve, NKH-1 posi- 
tive phenotype, these findings further suggest that cutaneous Leu 
7 + ve cells are predominantly cross-reacting T lymphocytes and 
not true NK cells. The restricted distribution of CD16/NKH-1 
positive cells around the squamoproliferative lesions of squamous 
cell carcinoma and keratoacanthoma is intriguing and may suggest a 
specific role for NK effector cells in these squamoproliferative le- 
sions. In no case did CD16/NKH-1 positive cells constitute more 
than 5% of the infiltrate, although the effector functions of NK 
cells may be a qualitative rather than a quantitative phenomenon [5]. 
We regard detection of the HNK-1 antigen by the antibody Leu 
7 as being insufficiently specific to be used as a marker for NK cells 
in cutaneous tissue and regard the detection of the more specific 
CD16 and NKH-1 antigens as being both theoretically and practi- 
cally superior for the purposes of cutaneous NK cell studies. 
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Dual Genotype in Cutaneous T Cell Lymphoma: Immunoglobulin Gene 
Rearrangement in Clonal T Cell Malignancy 
To the Editor: 
In their study, Berger et al [l] reported a surprisingly high incidence 
of dual genotype in cutaneous T cell lymphomas (CTCL). Four of 
13 case; in ldikemic phase presented b&h a TCR and’ an IgJH 
rearrangement in the blood. 
We should like to raise a point about this interesting article by a 
comparison with our own results. Like Whittaker [2], we failed to 
find an additional JH rearrangement to TCR gene rearrangement in 
peripheral blood of Stzary syndrome, and we were surprised by the 
absence of any genotypic study in skin lesions. 
We studied 20 skin biopsies of CTCL with both JH and beta 
TCR gene probes. We also found a high incidence of bigenotype: 5 
cases (20%) had both a TCR and IgJH rearrangement. Thus, the 
skin samples confirmed the results obtained from the blood studies. 
But, unlike Berger, in one case we had more than a single JH allele 
rearranged. 
Berger et al presented three hypotheses for dual genotype in 
CTCL but our results suggest that there is a fourth explanation: The 
pathology may not be monoclonal but oligoclonal. It is well-known 
that, in some cases, there are more than two rearranged bands sug- 
gesting B cell biclonality [3] or different T cell clones in separate 
skin lesions from the same patient [4]. One of our cases agreed with 
the oligoclonality theory. Two skin biopsies from the same patient 
were studied; the second biopsy had, besides the same rearranged 
IgJH band, two additional rearranged bands, although they had the 
same genotype with beta and gamma TCR gene probes. 
We should be interested to know if the authors have eliminated 
this explanation for the cases in which they did not perform geno- 
typic study on T cell enrichment of peripheral blood lymphocytes. 
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REPLY 
We have read the letter by Drs. Bignon et al concerning our manu- 
script entitled “Dual genotype in cutaneous T cell lymphoma: Im- 
‘munoglobulin gene rearrangement in clonal T cell malignancy” by 
Berger et al (J Invest Dermatol90:73 - 77,1988). We would like to 
respond to the points raised in this letter. 
We did not study the skin lesions of these patients as the goal of 
our investigation was to confirm leukemic disease dissemination in 
already diagnosed patients by DNA hybridization and compare this 
technology with previously developed methods. We were inter- 
ested to learn that skin samples studied by Dr. Bignon and associates 
also contained a dual genotype. We are surprised that this phenome- 
non was not detected in the peripheral blood of these patients but we 
do not know the stage of their disease at the time of the study. It may 
be that these cells were sequestered in the skin at an early stage of 
disease progression and may enter the periphery at a later time point. 
Dr. Bignon and colleagues also suggest an oligoclonal origin for 
some cases of cutaneous T cell lymphoma (CTCL) based on the 
presence of additional JH rearrangements found in the skin biopsy 
of one patient. The presence of additional rearrangements detected 
with the JH probe could reflect clonal evolution involving the 
second allele, deletion of heavy-chain gene sequences, or other 
complex exchanges. It is equally possible that this JH rearrange- 
ment represents a dual neoplasm as the authors apparently did not 
confirm that these rearrangements were restricted to the clonal T 
cell population. Although some cases of CTCL may be oligoclonal 
in origin we have demonstrated no evidence to support this conten- 
tion in our studies and have confirmed monoclonality by karyotypic 
analysis in several cases. 
We believe further studies are required to fully elucidate the 
nature of the transformational event in CTCL and the origin of this 
disease. 
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